

chain nodes :
 7 8 9 10 11 12 14
 ring nodes :
 1 2 3 4 5
 chain bonds :
 2-8 3-7 7-9 7-10 8-14 10-11 10-12
 ring bonds :
 1-2 1-5 2-3 3-4 4-5
 exact/norm bonds :
 1-2 1-5 2-3 2-8 3-4 3-7 4-5 7-9 7-10 8-14 10-11 10-12


G1:O,S

G2:Cb,Cy,Hy,Ak

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR



G1 O,S

G2 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:56:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 718 TO ITERATE

100.0% PROCESSED 718 ITERATIONS


113 ANSWERS

SEARCH TIME: 00.00.01

L2 113 SEA SSS FUL L1

=> d l2 1-10


L2 ANSWER 1 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 909011-38-7 REGISTRY
 ED Entered STN: 28 Sep 2006
 CN 2-Thiophenecarboxylic acid, 5-bromo-3-[[[2-ethoxy-2-oxoethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)
 MF C11 H12 Br N O5 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 2 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 909011-36-5 REGISTRY
 ED Entered STN: 28 Sep 2006
 CN 2-Thiophenecarboxylic acid, 3-[[[2-ethoxy-2-oxoethyl]amino]carbonyl]-5-(4-fluorophenyl)-, methyl ester (9CI) (CA INDEX NAME)
 MF C17 H16 F N O5 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 3 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 909011-18-3 REGISTRY
 ED Entered STN: 28 Sep 2006
 CN 2-Thiophenecarboxylic acid, 4-bromo-3-[[[2-ethoxy-2-oxoethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)
 MF C11 H12 Br N O5 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 893653-02-6 REGISTRY
 ED Entered STN: 17 Jul 2006
 CN INDEX NAME NOT YET ASSIGNED
 MF C24 H30 N2 O6 S
 SR Chemical Library
 Supplier: Princeton BioMolecular Research, Inc.
 LC STN Files: CHEMCATS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 5 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-20-7 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-{cyano-2-
 {[1,1-dimethylethyl]dimethylsilyl}oxy]ethyl]amino]phenyl]- (9CI) (CA
 INDEX NAME)
 MF C26 H30 Cl N5 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-19-4 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-{[2-[[[1,1-
 dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX
 NAME)
 MF C25 H31 Cl N4 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-18-3 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-{cyano-2-
 {[1,1-dimethylethyl]dimethylsilyl}oxy]ethyl]amino]phenyl]- (9CI) (CA
 INDEX NAME)
 MF C26 H30 Cl N5 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-17-2 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-{[2-[[[1,1-
 dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX
 NAME)
 MF C25 H31 Cl N4 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-01-4 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2-Thiophenecarboxylic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-
 (9CI) (CA INDEX NAME)
 MF C11 H7 Cl N2 O3 S
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890051-86-2 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-[5-chloro-2-pyridinyl]-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)
 MF C20 H16 Cl N5 O3 S . x C H4 O3 S
 SR CA
 LC STN Files: CA, CAPLUS

CH 1

CRN 890051-85-1
 CMF C20 H16 Cl N5 O3 S



CH 2

CRN 75-75-2
 CMF C H4 O3 S



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
192.05	192.26

FILE 'CAPLUS' ENTERED AT 14:56:20 ON 01 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Mar 2007 VOL 146 ISS 10
FILE LAST UPDATED: 28 Feb 2007 (20070228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12
L3 32 L2

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.47	192.73

FILE 'REGISTRY' ENTERED AT 14:57:01 ON 01 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITL data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2007 HIGHEST RN 923894-67-1
DICTIONARY FILE UPDATES: 28 FEB 2007 HIGHEST RN 923894-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10736742a.str



chain nodes :

7 8 9 10 11 12 14

ring nodes :

1 2 3 4 5

chain bonds :

2-8 3-7 7-9 7-10 8-14 10-11 10-12

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 2-8 3-4 3-7 4-5 7-9 7-10 8-14 10-11 10-12

isolated ring systems :

containing 1 :

G1:O,S

G2:Cb,Cy,Hy,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS


11:CLASS 12:CLASS 14:CLASS

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR



G1 O,S

G2 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l4 full

FULL SEARCH INITIATED 14:57:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 718 TO ITERATE

100.0% PROCESSED 718 ITERATIONS


83 ANSWERS

SEARCH TIME: 00.00.01

L5 83 SEA SSS FUL L4


=> d 15 1-12

L5 ANSWER 1 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 909011-38-7 REGISTRY
 ED Entered STN: 28 Sep 2006
 CN 2-Thiophenecarboxylic acid, 5-bromo-3-[[[2-ethoxy-2-oxoethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)
 MF C11 H12 Br N O5 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 909011-36-5 REGISTRY
 ED Entered STN: 28 Sep 2006
 CN 2-Thiophenecarboxylic acid, 3-[[[2-ethoxy-2-oxoethyl]amino]carbonyl]-5-(4-fluorophenyl)-, methyl ester (9CI) (CA INDEX NAME)
 MF C17 H16 F N O5 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 3 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 909011-18-3 REGISTRY
 ED Entered STN: 28 Sep 2006
 CN 2-Thiophenecarboxylic acid, 4-bromo-3-[[[2-ethoxy-2-oxoethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)
 MF C11 H12 Br N O5 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 4 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-20-7 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-{4-[cyano[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)
 MF C26 H30 Cl N5 O3 S S1
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 5 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-19-4 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)
 MF C25 H31 Cl N4 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 6 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-18-3 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-[cyano[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)
 MF C26 H30 Cl N5 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 7 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-17-2 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)
 MF C25 H31 Cl N4 O3 S Si
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 8 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890052-01-4 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2-Thiophenecarboxylic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]- (9CI) (CA INDEX NAME)
 MF C11 H7 Cl N2 O3 S
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 9 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890051-86-2 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)
 MF C20 H16 Cl N5 O3 S . x C H4 O3 S
 SR CA
 LC STN Files: CA, CAPLUS

CM 1

CRN 890051-85-1
 CMF C20 H16 Cl N5 O3 S




CM 2

CRN 75-75-2
 CMF C H4 O3 S



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 10 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890051-85-1 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)
 MF C20 H16 Cl N5 O3 S
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 11 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890051-84-0 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)
 MF C20 H16 Cl N5 O3 S . x C H4 O3 S
 SR CA
 LC STN Files: CA, CAPLUS

CM 1

CRN 890051-83-9
 CMF C20 H16 Cl N5 O3 S




CM 2

CRN 75-75-2
 CMF C H4 O3 S



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 12 OF 83 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 890051-83-9 REGISTRY
 ED Entered STN: 29 Jun 2006
 CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-(2-imino-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)
 MF C20 H16 Cl N5 O3 S
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
195.95	388.68

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:58:21 ON 01 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Mar 2007 VOL 146 ISS 10
FILE LAST UPDATED: 28 Feb 2007 (20070228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 15

L6 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:919505 CAPLUS
 DOCUMENT NUMBER: 145:314973
 TITLE: Preparation of thienopyridine carboxamides as hypoxia inducible factor (HIF) modulators
 INVENTOR(S): Turtle, Eric D.; Flippin, Lee A.; Arend, Michael P.; Cheng, Heng
 PATENT ASSIGNEE(S): Fibrogen, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 44pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006199836	A1	20060907	US 2006-367969	20060302
WO 2006094292	A2	20060908	WO 2006-US8117	20060302
WO 2006094292	A3	20061228		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.: US 2005-658131P P 20050302
 OTHER SOURCE(S): MARPAT 145:314973
 G1



AB Title compds. I [wherein q = 0 or 1; one of X and Y is S, and the other is CR7; R1 = OH, (un)substituted alkoxy, aryloxy, etc.; R2 = H, D or Me; R3 = H, D or (un)substituted alkyl; R4 = H or (un)substituted alkyl; R5 = H, halo, (un)substituted alkyl, etc.; R6, R7 = H, OH, halo, etc.] and pharmaceutically acceptable salts, single stereoisomers, mixts. of


L6 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 stereoisomers, esters, and prodrugs thereof, which are capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) (no data), were prepd. For instance, II was synthesized by condensation of the corresponding Bu ester with glycine in the presence of sodium methoxide in methanol. I were reported to be active in several biol. assays (no data). The invented compds. and their pharmaceutical compns. are useful for the treatment and prevention of disorders mediated at least in part by hypoxia inducible factor (HIF) and/or erythropoietin (EPO), such as anemia.


IT 909011-38-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of thienopyridine carboxamides as hypoxia inducible factor (HIF) modulators)

RN 909011-38-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-bromo-3-[(2-ethoxy-2-oxoethyl)amino]carbonyl-, methyl ester (9CI) (CA INDEX NAME)



IT 909011-18-3P 909011-36-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thienopyridine carboxamides as hypoxia inducible factor (HIF) modulators)

RN 909011-18-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-bromo-3-[(2-ethoxy-2-oxoethyl)amino]carbonyl-, methyl ester (9CI) (CA INDEX NAME)




RN 909011-36-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(2-ethoxy-2-oxoethyl)amino]carbonyl-5-(4-fluorophenyl)-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:542131 CAPLUS
 DOCUMENT NUMBER: 145:46051
 TITLE: Preparation of 2-imino-3-phenyloxazolidines and related compounds for the treatment of thromboembolic diseases
 INVENTOR(S): Roehrig, Susanne; Pohlmann, Jens; Arndt, Sabine; Jeske, Mario; Akkaba, Metin; Perzborn, Elisabeth; Gerdes, Christoph; Schlemmer, Karl-Heinz; Tuch, Arunarith; Lobell, Mario; Nell, Peter; Burkhardt, Nils
 PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: F1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058630	A1	20060608	WO 2005-EP12465	20051122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004058062	A1	20060608	DE 2004-102004058062	20041202
PRIORITY APPL. INFO.: DE 2004-102004058062A				20041202

OTHER SOURCE(S): MARPAT 145:46051
 G1




AB Title compds. I [Y = (CH₂)_n; n = 1-3; R₁ = H, alkyl, CN, etc.; R₂, R₃ = H, halo, CN, etc.; A = phenylene, 5 or 6-membered heteroaryl ring with proviso; Z = Ph, pyridyl, pyrimidinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, methanesulfonic acid mediated cyclization of cyanoamine II afforded the methanesulfonic acid salt of claimed phenyloxazolidine III in 81% yield. In blood-coagulation factor Xa inhibition assays, 4-examples of compds. I exhibited IC₅₀ values ranging 0.3-4.4 nM.

IT 890051-83-9P 890051-84-OP 890051-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-imino-3-phenyloxazolidines and related compds. for the treatment of thromboembolic diseases)

RN 890051-83-9 CAPLUS

CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-(2-imino-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 890051-84-0 CAPLUS

CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CH 1

CRN 890051-83-9

CHF C20 H16 Cl N5 O3 S



CH 2


CRN 75-75-2

CHF C H4 O3 S



RN 890051-85-1 CAPLUS

CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 890051-86-2 CAPLUS

CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-(2-imino-3-oxazolidinyl)phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CH 1

CRN 890051-85-1

CHF C20 H16 Cl N5 O3 S



CH 2

CRN 75-75-2

CHF C H4 O3 S




IT 890052-01-4P 890052-17-2P 890052-18-3P

890052-19-4P 890052-20-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-imino-3-phenyloxazolidines and related compds. for the treatment of thromboembolic diseases)


RN 890052-01-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(5-chloro-2-pyridinyl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 890052-17-2 CAPLUS

CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 890052-18-3 CAPLUS

CN 2,3-Thiophenedicarboxamide, N3-(5-chloro-2-pyridinyl)-N2-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 890052-19-4 CAPLUS
CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)





RN 890052-20-7 CAPLUS
CN 2,3-Thiophenedicarboxamide, N2-(5-chloro-2-pyridinyl)-N3-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2006:381034 CAPLUS
DOCUMENT NUMBER: 144:432826
TITLE: Preparation of thieno-fused ring heterocycle compounds via cyclization reaction as antitumor agents
INVENTOR(S): Ward, John; Jain, Ram; James, Donald; Verheij, Herman
PATENT ASSIGNEE(S): J. J. Schultz, Jan C. C.
SOURCE: Compass Pharmaceuticals LLC, USA
PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044826	A2	20060427	WO 2005-US37307	20051018
WO 2006044826	A3	20060921		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-620615P P 20041020
OTHER SOURCE(S): MARPAT 144:432826
GI



AB Thieno-fused ring heterocycle I, wherein W is carbon, nitrogen; R and X together with the carbons which they are attached form a 5-14 membered aryl, heteroaryl, cycloalkyl, heterocycloalkyl ring; Y is substituted amine, amide, NO₂; X is substituted amine, amide, carboxylate, CH=CH-COOR'; R' is H, alkyl; X and Y together with the carbons which they are attached form heterocycle, were prepared for treating tumors. Thus, thiophene II was prepared via cyclization of cyclo-heptanone with t-BuO(CO)CH₂CN and sulfur in EtOH at 45 °C and tested in vitro as antitumor agent against ovary, sarcoma, and lung tumors (IC₅₀ =




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

0.0142-21.7 μM). Examples of specific tumor types that the compds. may be used to treat include, but are not limited to sarcoma, melanoma, neuroblastoma, carcinoma (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinoma), and mesothelioma.

IT 352702-07-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thieno-fused ring heterocycle compds. via cyclization reaction as antitumor agents)

RN 352702-07-9 CAPLUS
CN 2,3-Thiophenedicarboxamide, 4-bromo-N,N'-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:87597 CAPLUS
DOCUMENT NUMBER: 144:304503
TITLE: Dual Binding Mode of a Novel Series of DHODH Inhibitors
AUTHOR(S): Baumgartner, Roland; Walloschek, Markus; Kralik, Martin; Gotschlich, Astrid; Tasler, Stefan; Mies, Jan; Leban, Johann
CORPORATE SOURCE: 4SC AG, Martinsried, 82152, Germany
SOURCE: Journal of Medicinal Chemistry (2006), 49(4), 1239-1247
CODEN: JMCHEM; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Human dihydroorotate dehydrogenase (DHODH) represents an important target for the treatment of hyperproliferative and inflammatory diseases. In the cell DHODH catalyzes the rate-limiting step of the de novo pyrimidine biosynthesis. DHODH inhibition results in beneficial immunosuppressant and antiproliferative effects in diseases such as rheumatoid arthritis. Here, we present high-resolution X-ray structures of human DHODH in complex with a novel class of low mol. weight compds. that inhibit the enzyme in the nanomolar range. Some compds. showed an interesting dual binding mode within the same cocrystal strongly depending on the nature of chemical substitution. Measured in vitro activity data correlated with the prevailing mode of binding and explained the observed structure-activity relationship. Addnl., the X-ray data confirmed the competitive nature of the inhibitors toward the putative ubiquinone binding site and will guide structure-based design and synthesis of mol. with higher activity.


IT 717142-75-1 717142-76-2
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual binding mode of novel series of DHODH inhibitors)
RN 717142-75-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 717142-76-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3,5-difluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1251585 CAPLUS
DOCUMENT NUMBER: 144:150196
TITLE: Biphenyl-4-ylcarbamoyl thiophenecarboxylic acids as potent DHODH inhibitors
AUTHOR(S): Leban, Johann; Kralik, Martin; Mies, Jan; Baumgartner, Roland; Gassen, Michael; Tasler, Stefan
CORPORATE SOURCE: 4SC AG, Martinsried, 82152, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(2), 267-270
CODEN: BMCLEB; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:150196
GI




AB A previously discovered dihydroorotate dehydrogenase (DHODH) inhibitor series was further improved by replacing the cyclopentene ring by aromatic heterocycles. Different isomers of these compds., e.g. 1 (R1 = R2 = HO2C, R3 = H; R1 = R3 = HO2C, R2 = H; R1 = H, R2 = R3 = HO2C), were prepared by the directed ortho-metalation procedure. The compds. are more active than the corresponding cyclopentene analogs and show potent effects on peripheral blood mononuclear cell (PBMC) proliferation.

IT 717142-61-5 717142-62-6 717142-64-8
717142-67-1 717142-71-7
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation and biol. evaluation of biphenylcarbamoyl thiophene- and furancarboxylic acids as dihydroorotate dehydrogenase inhibitors and peripheral blood mononuclear cell antiproliferative agents)
RN 717142-61-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1,1'-biphenyl]-4-ylamino]carbonyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 717142-62-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[2'-ethoxy-3,5-difluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 717142-64-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3'-ethoxy-3,5-difluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 717142-67-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[2,3,5,6-tetrafluoro-2'-methoxy[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 717142-71-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(2-chloro-2'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 717142-75-1P 873843-81-3P 873843-82-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. evaluation of biphenylcarbamoyl thiophene- and furancarboxylic acids as dihydroorotate dehydrogenase inhibitors and peripheral blood mononuclear cell antiproliferative agents)
RN 717142-75-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 873843-81-3 CAPLUS
CN 2,4-Thiophenedicarboxylic acid, 3-[[[(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 873843-82-4 CAPLUS
CN 2,5-Thiophenedicarboxylic acid, 3-[[[(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)

2004:878168 CAPLUS
ACCESSION NUMBER: 141:360665
DOCUMENT NUMBER:
TITLE: Synergistic methods and compositions using insulin-like growth factor 1 receptor (IGF1R) inhibitors with additional kinase inhibitors for treating cancer
INVENTOR(S): Carboni, Joan M.; Hurlburt, Warren W.; Gottardis, Marco M.; Lee, Francis Y.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 676,214.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209930	A1	20041021	US 2004-814199	20040331
CA 2500714	A1	20040415	CA 2003-2500714	20031001
US 2004072760	A1	20040415	US 2003-677067	20031001
AU 2003275364	A1	20040423	AU 2003-275364	20031001
US 2004106605	A1	20040603	US 2003-676214	20031001
EP 1551411	A2	20050713	EP 2003-759640	20031001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200603867	T	20060202	JP 2004-541997	20031001
WO 2005094376	A2	20051013	WO 2005-US10820	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
			US 2002-415416P	P 20021002
			US 2003-676214	A2 20031001
			US 2003-677067	A2 20031001
			WO 2003-US31091	W 20031001
			US 2004-814199	A 20040331


OTHER SOURCE(S): MARPAT 141:360665
AB Combination therapies using IGF1R inhibitors in combination with adnl. kinase inhibitors are described for the synergistic treatment of cancer.
IT 302959-65-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IGF1 receptor inhibitors with adnl. kinase inhibitors for synergistic treatment of cancer)
RN 302959-65-5 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[[(2-acetyl-3-thienyl)carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



16 ANSWER 7 OF 23 CAPLUS 1004:5550947 CAPLUS 101:106361
 ACCESSION NUMBER: 7004:5550947 CAPLUS
 DOCUMENT NUMBER: 101:106361
 TITLE: Preparation of aromatic compounds as
 anti-inflammatory, immunomodulatory and
 antiproliferative agents
 INVENTOR(S): Lebnan, Johann; Tasler, Stefan
 PATENT ASSIGNEE(S): 45C A.-G., Germany
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: P1XKX2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004:056797		A1	2004:0708	2003:1217
WU: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TN, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZH, ZW			WO 2003-EP14433	
RW: BV, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BF, BG, KZ, MD, RU, TJ, TH, AT, BE, BI, BR, BY, CA, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SH, SN, TD, TG				
CA 2509139	A1	2004:0708	CA 2003-2509139	2003:1217
AU 2003:293914	A1	2004:0714	AU 2003-293914	2003:1217
US 2004176458	A1	2004:0909	US 2003-736711	2003:1217
US 7071355	B2	2006:0704		
US 2004:192758	A1	2004:0930	US 2003-736742	2003:1217
EP 1578941	A1	2005:0828	EP 2003-789317	2003:1217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, SG, PT, IE, SI, LT, LV, FI, HK, CY, AU, TR, GQ, CZ, KE, HU, SK				
BR 2003:17687	A	2005:1122	BR 2003-17687	2003:1217
CN 1732163	A	2006:0208	CN 2003-80107354	2003:1217
CN 1732147	A	2006:0208	CN 2003-80107355	2003:1217
JP 2006514023	T	2006:0227	JP 2004-561331	2003:1217
JP 2007027193	A1	2007:0201	US 2004-736739	2004:1110
ZA 2005:004387	A	2006:0222	ZA 2005-4387	2005:0530
IN 2005MN00815	A	2005:1111	IN 2005-MN815	2005:0722
PRIORITY APPLN. INFO.1			DE 2002-1026800	2003:1223
			US 2002-4352589	P 2002:1223
			US 2002-4352859	P 2002:1223
			US 2002-5629922	P 2003:1205
			WO 2003-EP14433	P 2003:1217

OTHER SOURCE(S): MARPAT 141:106361
GI




AB Aromatic compds. of formula I [ring A = heteroatom: X = S, O, N, (substituted) N, SO₂, SO, D = O, S, SO₂, (substituted) N, CH₂; Z1, Z2 = O, S, (substituted) N; R = H, halo, OH, cycloalkyl, alkyl, etc.; R1 = H, alkyl; R2 = H, (substituted) OH, (substituted) NH, etc.; R3 = H, alkyl, cycloalkyl, aryl, etc.; E = alkyl, cycloalkyl, etc.; Y = H, halo, alkyl, etc.; m, n, p = 0-1; q = 0-3] are prepared as anti-inflammatory, immunomodulatory and antiproliferative agents. Thus, I1 was prepared. Many of the prepared compds. had IC₅₀ values of < 1μl against dihydrocorotate -


dehydrogenase (DHDH);
 717142-61-SP 717142-62-6P 717142-64-8P
 717142-65-9P 717142-67-1P 717142-68-2P
 717142-69-3P 717142-71-7P 717142-73-9P
 717142-75-1P 717142-76-2P 717142-77-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses).

(preparation of biaryl thiophene- and furan-carboxylic acids as anti-inflammatory, immunomodulatory and antiproliferative agents)


RD	717142-61-5	CAPLUS
CN	2-Thiophenecarboxylic acid, 3-([1,1'-biphenyl]-4-ylamino)carbonyl)- (9CI) (CA INDEX NAME)	




RN 717142-62-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[2'-ethoxy-3,5-difluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 717142-64-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[(3'-ethoxy-3,5-difluoro[1,1'-biphenyl]-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 717142-65-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(3,5-difluoro-2',4'-dimethoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 717142-67-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(2,3,5,6-tetrafluoro-2'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 717142-68-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(2'-chloro-3,5-difluoro[1,1'-biphenyl]-4-yl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 717142-73-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 717142-75-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 717142-69-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(2',3,5-trifluoro[1,1'-biphenyl]-4-yl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 717142-71-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(2-chloro-2'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl- (9CI) (CA INDEX NAME)



RN 717142-76-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3,5-difluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]amino]carbonyl- (9CI) (CA INDEX NAME)



RN 717142-77-3 CAPLUS
CN 2-Furancarboxylic acid, 3-[[[1,1'-biphenyl]-4-yl]amino]carbonyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2004:550931 CAPLUS
DOCUMENT NUMBER: 141:99739
TITLE: Dihydroorotate dehydrogenase (DHODH) inhibitors and method for their identification
INVENTOR(S): Letan, Johann; Kramer, Bernd; Baumgartner, Roland; Aulinger-Fuchs, Katharina; Tasler, Stefan
PATENT ASSIGNEE(S): 45C A.-G., Germany
SOURCE: PCT Int. Appl., 357 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056747	A1	20040708	WO 2003-EP14435	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, GU, HA, HE, HO, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PU, PY, RE, RO, RU, SD, SE, SG, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TF, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, NI, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PU, PY, RE, RO, RU, SD, SE, SG, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TF, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
EP 1541198	A1	20050615	EP 2003-28137	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2003300530	A1	20040714	AU 2003-300530	20031217
US 2004176458	A1	20040909	US 2003-736711	20031217
US 7071355	B2	20060704		
US 2004192758	A1	20040930	US 2003-736742	20031217
EP 1581478	A1	20051005	EP 2003-813575	20031217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2007027193	A1	20070201	US 2004-736739	20041110
PRIORITY APPLN. INFO.:				
			DE 2002-10260799	A 20021223
			DE 2002-10260800	A 20021223
			EP 2003-28137	A 20031205
			US 2002-435258P	P 20021223
			US 2002-435285P	P 20021223
			US 2003-526992P	P 20031205
			WO 2003-EP14435	W 20031217

OTHER SOURCE(S): MARPAT 141:99739
AB The present invention relates to compds. containing non-aromatic ring systems or heteroarom. ring systems, which are capable of binding to the ubiquinone binding site of DHODH. Methods for identification of such compds. are also disclosed.
IT 717142-76-2D, complexes with dihydroorotate dehydrogenase
717824-37-8D, complexes with dihydroorotate dehydrogenase
RL: PRP (Properties)
(dihydroorotate dehydrogenase inhibitors and inhibitor identification method)
RN 717142-76-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3,5-difluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 717824-37-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3,5-difluoro-3'-methoxy[1,1'-biphenyl]-4-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:220082 CAPLUS
DOCUMENT NUMBER: 140:253556
TITLE: Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors
INVENTOR(S): Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweiko, Arthur M. P.; Barrish, Joel C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of U.S. 6,596,746.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004054186	A1	20040318	US 2003-395503	20030324
US 7125875	B2	20061024		
US 6596746	B1	20030722	US 2000-548929	20000413
US 2004024208	A1	20040205	US 2003-378372	20030303
US 6979694	B2	20051227		
US 2004073026	A1	20040415	US 2003-378461	20030303
US 7091223	B2	20060815		
US 2004077875	A1	20040422	US 2003-378373	20030303
AU 2004223828	A1	20041007	AU 2004-223828	20040323
CA 2519898	A1	20041007	CA 2004-2519898	20040323
WO 2004085388	A2	20041007	WO 2004-US8827	20040323
WO 2004085388	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HA, HE, HO, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, PU, PY, RE, RO, RU, SD, SE, SG, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TF, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, HS, NI, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PU, PY, RE, RO, RU, SD, SE, SG, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TF, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
EP 1610780	A2	20060104	EP 2004-758053	20040323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008782	A	20060328	BR 2004-8782	20040323
CN 1764454	A	20060426	CN 2004-80007845	20040323
JP 2006523216	T	20061012	JP 2006-507475	20060323
US 2005261305	A1	20051124	US 2005-138793	20050525
US 2005288303	A1	20051229	US 2005-138942	20050525
US 7153856	B2	20061226		
NO 2005004359	A	20051019	NO 2005-4359	20050920
US 2006079563	A1	20060413	US 2005-271626	20051110
PRIORITY APPLN. INFO.:				
			US 1999-129510P	P 19990415
			US 2000-548929	A2 20000413
			US 2003-378373	A1 20030303
			US 2003-395503	A 20030324
			WO 2004-US8827	W 20040323

OTHER SOURCE(S): MARPAT 140:253556
GI



AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical composition comprising the title compds. is claimed.


IT 302959-65-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302959-65-5 CAPLUS

CN 5-Thiazolecarboxamide, 2-[(2-acetyl-3-thienyl)carbonyl]amino-4-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:58069 CAPLUS

DOCUMENT NUMBER: 138:122639

TITLE: Preparation of thiazols and related compounds as telomerase inhibitors

INVENTOR(S): Priepke, Henning; Kauffmann-Hefner, Iris; Haeucl, Norbert; Damm, Klaus; Schnapp, Andreas

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 88 pp.

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006443	A2	20030123	WO 2002-EP7558	20020706
WO 2003006443	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RV: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10133665	A1	20030130	DE 2001-10133665	20010711
US 2003055263	A1	20030320	US 2002-192456	20020710
PRIORITY APPLN. INFO.:				
			DE 2001-10133665	A 20010711
			US 2001-307449P	P 20010724

OTHER SOURCE(S): MARPAT 138:122639




G1

L6 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(drug candidate; prepn. of thiazols and related compds. as telomerase inhibitors)

RN 488816-11-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[4-(2-naphthalenyl)-2-thiazolyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



AB Title compds. R1-A-B-R2 (I) [R1 = (un)substituted Ph, phenylalkyl, phenylalkenyl, etc.; A = (un)substituted phenylalkyl; B = HN, NHC(=O), CONH, etc.; R2 = CO2, (un)substituted cycloalkyl, cycloalkenyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, coupling of thiazol II and phthalic anhydride afforded claimed benzoic acid III in 30% yield. In telomerase inhibition studies, 3-specific examples of I exhibited IC50 values ranging from < 1 - < 5 µM, e.g., IC50 value of compound III was < 5 µM. Compds. I are claimed useful as telomerase inhibitors.

IT 488816-11-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER:

2002:237356 CAPLUS

DOCUMENT NUMBER:

136:263090

TITLE:

Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1a and/or MCP-1 on target cells

INVENTOR(S):

Shiota, Tatsuki; Kataoka, Ken-ichi; Imai, Minoru; Tsutsumi, Takaharu; Sudoh, Haseki; Sogawa, Ryo; Morita, Takuya; Hada, Takahiko; Muroga, Yumiko; Takenouchi, Osami; Furuya, Minoru; Endo, Noriaki; Farby, Christine M.; Morse, Wilna; Teig, Steven

PATENT ASSIGNEE(S):

Teijin Limited, Japan; Dupont Pharmaceuticals Research Laboratories

SOURCE:

U.S., 364 pp., Cont. of U.S. Ser. No. 554,562.

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6362177	B1	20020326	US 2001-905078	20010716
US 6451042	B1	20020917	US 2000-554562	20000516
US 6410566	B1	20020625	US 2001-905077	20010716
PRIORITY APPLM. INFO.:			US 2000-554562	A3 20000516
			US 1997-972484	B1 19971118
			US 1998-55285	B1 19980406
			US 1998-133434	B1 19980813
			WO 1998-US23254	W 19981117

OTHER SOURCE(S):

MARPAT 136:263090

G1




AB The title compds. [I; R1 = (un)substituted Ph, cycloalkyl, heteroaryl, etc.; R2 = H, alkyl, alkoxy, carbonyl, etc.; j = 0-2; k = 0-2; m = 3-4 and k+m = 5 or 6; n = 0-1; R3 = H, alkyl; R4, R5 = H, OH, Ph, etc.; p, q = 0-1; G = CO, SO, CO2, etc.; R6 = Ph, cycloalkyl, cycloalkenyl, etc.] and their pharmaceutically acceptable acid addition salts which inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells and

L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN


(Continued)

PAGE 2-A




RN 226232-26-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-acetyl-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A

RN 226232-88-8 CAPLUS

L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN

(Continued)


may be useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues, were prepd. Thus, reaction of N-benzoylglycine with 3-amino-1-(4-chlorobenzyl)pyrrolidine.ZHCl in the presence of 3-ethyl-1-[3-(dimethylaminopropyl)]carbodiimide.HCl, 1-hydroxybenzotriazole and Et3N in CHCl3 afforded 95% II which showed 50-80% inhibition of MIP-1a binding to THP-1 cells at 10 μM.

IT 226231-48-7P, 3-Thiophenecarboxamide, 2-acetyl-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]-226232-26-4P, 3-Thiophenecarboxamide, 2-acetyl-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl]-226232-88-8P, 3-Thiophenecarboxamide, 2-acetyl-N-[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]-226250-84-6P, 3-Thiophenecarboxamide, 2-acetyl-N-[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]-, mono(trifluoroacetate) RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amine deriva. for inhibition of action of chemokines such as MIP-1a and/or MCP-1 on target cells)

RN 226231-48-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-acetyl-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN


(Continued)

CN 3-Thiophenecarboxamide, 2-acetyl-N-[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226250-84-6 CAPLUS


CN 3-Thiophenecarboxamide, 2-acetyl-N-[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 226232-88-8

CHP C25 H32 Cl N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:12413 CAPLUS

DOCUMENT NUMBER: 134:71497

TITLE: Preparation of heterocyclic dicarboxylic acid diamide derivatives as agricultural and horticultural insecticides

INVENTOR(S): Katsuhira, Takeshi; Furuya, Takashi; Gotoh, Makoto; Tohishi, Masanori; Takashi, Hideo; Sakata, Kazuyuki; Morimoto, Masayuki; Seo, Akira

PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 160 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000575	A1	20010104	WO 2000-JP4136	20000623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, FL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000011818	A	20020319	BR 2000-11818	20000623
EP 1188745	A1	20020320	EP 2000-940823	20000623
EP 1188745	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
HU 200201555	A2	20020828	HU 2002-1555	20000623
AU 761273	B2	20030529	AU 2000-55689	20000623
AT 348804	T	20070115	AT 2000-940823	20000623
JP 2001064258	A	20010313	JP 2000-191500	20000626
ZA 2001010006	A	20030205	ZA 2001-10006	20011205
US 6747041	B1	20040608	US 2002-18463	20020410
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 134:71497-G1				




AB The title compds. I [R1, R2 and R3 represent each H, optionally halogenated C3-6 cycloalkyl, etc.; Het represents a 5- or 6-membered heterocycle; X and Y represent each halocycano, nitro, optionally halogenated C3-6 cycloalkyl, optionally substituted Ph, an optionally substituted heterocycle, etc.; n is from 0 to 3; m is from 1 to 5; Z1 and Z2 represent each O or S; and B1 to B4 represent each C or N] are prepared. I have an excellent controlling effect on pest insects such as diamond-back moth (*Plutella xylostella*) and tobacco cutworm (*Spodoptera litura*). The title compound II at 500 ppm gave $\geq 90\%$ control of *Plutella xylostella*.


IT 314762-88-4P 314762-89-5P 314762-90-8P
314762-91-9P 314762-92-0P 314762-93-1P
314763-03-6P 314763-04-7P 314763-05-8P
314763-06-9P 314763-07-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic dicarboxylic acid diamide derivs. as agricultural and horticultural insecticides)


RN 314762-88-4 CAPLUS
CN 2,3-Furandicarboxamide, N3-(1-methylethyl)-N2-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 314762-89-5 CAPLUS
CN 2,3-Furandicarboxamide, 4,5-dimethyl-N3-(1-methylethyl)-N2-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 314762-90-8 CAPLUS
CN 2,3-Furandicarboxamide, N3-(1,1-dimethylethyl)-N2-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 314762-91-9 CAPLUS
CN 2,3-Thiophenedicarboxamide, N3-(1-methylethyl)-N2-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 314762-92-0 CAPLUS
CN 2,3-Thiophenedicarboxamide, 4-iodo-N3-(1-methylethyl)-N2-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 314762-93-1 CAPLUS
CN 2,3-Thiophenedicarboxamide, N3-(1,1-dimethylethyl)-N2-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 314763-03-6 CAPLUS
CN 2,3-Furandicarboxamide, 4,5-dimethyl-N2-(1-methylethyl)-N3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 314763-04-7 CAPLUS
CN 2,3-Thiophenedicarboxamide, N2,N2-diethyl-N3-[2-methyl-4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 314763-05-8 CAPLUS
CN 2,3-Thiophenedicarboxamide, N2,N2-diethyl-N3-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 314763-06-9 CAPLUS
CN 2,3-Thiophenedicarboxamide, N2,N2-diethyl-N3-[2-methyl-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 314763-07-0 CAPLUS
CN 2,3-Thiophenedicarboxamide, N2,N2-diethyl-N3-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 16 13-23 ibib abs hitstr

L6 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2000:961644 CAPLUS
 DOCUMENT NUMBER: 134:29705
 TITLE: Preparation of squaric acid derivatives as cell adhesion molecules
 INVENTOR(S): Langham, Barry John; Alexander, Rikki Peter; Head, John Clifford; Linsley, Janeen Marsha; Porter, John Robert; Archibald, Sarah Catherine; Warrelow, Graham John
 PATENT ASSIGNEE(S): Celltech Chiroscience Limited, UK
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073260	A1	20001207	WO 2000-GB2020	20000526
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6518283	B1	20030211	US 2000-579317	20000525
CA 2375218	A1	20001207	CA 2000-2375218	20000526
EP 1181266	A1	20020227	EP 2000-935341	20000526
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2003500467	T	20030107	JP 2000-621327	20000526
AU 776704	B2	20040916	AU 2000-50889	20000526
US 2003162799	A1	20030828	US 2002-319272	20021213
PRIORITY APPLN. INFO.:			GB 1999-12640	A 19990528
			GB 2000-2858	A 20000208
			US 2000-579317	A3 20000525
			WO 2000-GB2020	W 20000526


OTHER SOURCE(S): MARPAT 134:29705
 GI



AB Squaric acid derivs. 1 [R1 is an integrin binding group; R2 is a hydrogen atom or a C1-6 alkyl group; L1 is a covalent bond or a linker atom or group; n = 0, 1; Alk1 is an optionally substituted aliphatic chain; R3 is H or an optionally substituted heteroaliph., cycloaliph., heterocycloaliph., polycycloaliph., polyheterocycloaliph., aromatic or heteroarom. group] and their salts, solvates, hydrates and N-oxides were prepared as inhibitors of the binding of integrins to their ligands. Thus, treatment of Et (S)-3-(4-aminophenyl)-2-(tert-butoxycarbonylamino)propionate with

L6 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 3,5-dichloro-4-pyridinecarboxylic acid, deprotection, reaction with 3,4-diisopropoxy-3-cyclobutene-1,2-dione, propylamine, and sapon. afforded (S)-3-(4-(3,5-dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4-dioxocyclobut-1-enylamino)propanoic acid. Comps. of the invention in which R1 is an $\alpha 4$ integrin binding group generally have IC50 values <1 μ M in the $\alpha 4 \beta 1$ and $\alpha 4 \beta 7$ assays.
 IT R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of squaric acid derivs. as cell adhesion mols.)
 RN 312294-76-1 CAPLUS
 CN L-Phenylalanine, 4-[[[(2-acetyl-3-thienyl)carbonyl]amino]-N-[3,4-dioxo-2-(propylamino)-1-cyclobuten-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2000:824101 CAPLUS
 DOCUMENT NUMBER: 134:5154
 TITLE: Preparation of cyclic amine derivatives as remedies or preventives for diseases in association with chemokines or chemokine receptors
 INVENTOR(S): Shiota, Tatsuki; Miyagi, Fuminori; Kamimura, Takashi; Ohta, Tomohiro; Takano, Yasuhiro; Horiuchi, Hideki
 PATENT ASSIGNEE(S): Teijin Limited, Japan
 SOURCE: PCT Int. Appl., 405 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069432	A1	20001123	WO 2000-JP3203	20000518
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GR, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2373942	A1	20001123	CA 2000-2373942	20000518
EP 1179341	A1	20020213	EP 2000-927808	20000518
EP 1179341	B1	20051109		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO			
NZ 515374	A	20040924	NZ 2000-515374	20000518
AU 779954	B2	20050224	AU 2000-46147	20000518
AT 308985	T	20051115	AT 2000-927808	20000518
ES 2250132	T3	20060416	ES 2000-927808	20000518
NO 2001005599	A	20011116	NO 2001-5599	20011116
PRIORITY APPLN. INFO.:			JP 1999-175856	A 19990518
			JP 1999-251464	A 19990906
			WO 2000-JP3203	W 20000518


OTHER SOURCE(S): MARPAT 134:5154
 GI




AB Remedies or preventives for diseases in association with chemokines such as MIP-1 α and/or MCP-1 or chemokine receptors such as CCR1 or CCR2 contain as the active ingredient N-acyl-amino acid N-cyclic amino or N-cyclic aminoalkyl-amide derivs. represented by general formula [1]: (un)substituted Ph, C3-8 cycloalkyl, aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S, and/or N; R2 = H, (un)substituted C1-6 alkyl, C2-7 alkoxyalkyl, (un)substituted Ph; p1, n1 = 0-2; m = 2-4; n = 0, 1; R3 = H, (un)substituted C1-6 alkyl; R4, R5 = H, OH, (un)substituted Ph or C1-6 alkyl; or R4 and R5 are combined together to

L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 form a 3- to 5-membered hydrocarbonyl; p, q = 0, 1; G = CO, SO2, CO2, NR7CO, CONR7, NR7SO2, or SO2NR7, NHCONH, NHCSNH, NH CO2, O2CNH; R7 = H, C1-6 alkyl; or R7 and R5 are combined together to form C2-5 alkylene; R6 = (un)substituted Ph, C3-8 cycloalkyl, C3-6 cycloalkenyl, CH2Ph, or arom. heterocyclyl contg. 1-3 heteroatoms selected from O, S, and/or N, wherein Ph, CH2Ph, or arom. heterocyclyl group is optionally fused with (un)substituted benzene or arom. heterocyclyl contg. 1-3 heteroatoms selected from O, S, and/or N), pharmaceutically acceptable acid-adducts thereof, or pharmaceutically acceptable C1-6 alkyl-adducts thereof. The above diseases include destruction of bone or cartilage (e.g. arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, injury, and tumor), nephritis, kidney diseases, glomerulus or interstitial nephritis, nephrotic syndrome, demyelinating disease, or multiple sclerosis. Thus, N-3-ethoxybenzyl-D-methionine-N-[1-(4-chlorobenzyl)-4-piperazinylmethyl]amide in vitro inhibited the binding of human MIP-1 α to THP-1 cells by >80% at 2 μ M.
 IT 226231-48-7P 226232-26-4P 226232-88-8P
 R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyclic amine derivs. as remedies or preventives for diseases in association with chemokines or chemokine receptors)
 RN 226231-48-7 CAPLUS
 CN 3-Thiophenecarboxamide, 2-acetyl-N-[2-[[[1-(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226232-26-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-acetyl-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226232-88-8 CAPLUS

L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:756524 CAPLUS
DOCUMENT NUMBER: 133:321878
TITLE: Preparation of cyclic protein tyrosine kinase inhibitors
INVENTOR(S): Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Dowsyko, Arthur M. P.; Barrish, Joel C.; Wityak, John
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062778	A1	20001026	WO 2000-US9753	20000412
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GL, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2366932	A1	20001026	CA 2000-2366932	20000412
AU 200042338	A	20001102	AU 2000-42338	20000412
AU 779089	B2	20050106		
EP 1169038	A1	20020109	EP 2000-922102	20000412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009721	A	20020213	BR 2000-9721	20000412
TR 200102969	T2	20020821	TR 2001-2969	20000412
JP 2002542193	T	20021210	JP 2000-611914	20000412
HU 200202708	A2	20021228	HU 2002-2708	20000412
NZ 513639	A	20040227	NZ 2000-513639	20000412
RU 2260592	C2	20050920	RU 2001-130452	20000412
ZA 2001007204	A	20021202	ZA 2001-7204	20010830
IN 2001MN01138	A	20050304	IN 2001-MN1138	20010919
NO 2001004970	A	20011210	NO 2001-4970	20011012
NO 322470	B1	20061009		
US 2005261305	A1	20051124	US 2005-138793	20050525
US 2005288303	A1	20051229	US 2005-138942	20050526
US 7153856	B2	20061226		
US 2006079563	A1	20060413	US 2005-271626	20051110

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 133:321878
GI

L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Thiophenecarboxamide, 2-acetyl-N-[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R1C(CH₃)₂ (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day.
IT 302959-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of cyclic protein tyrosine kinase inhibitors)
RN 302959-65-5 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[[(2-acetyl-3-thienyl)carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

WO 9937618

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GE, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG

US 6329372

AU 9924320

EP 1051399

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2002501051

US 2002035127

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

AB

Phenylalanine derivs. 4-([R1(Alk1)C(L1)]C6H2R2Arb(Alk2)mCHRR2NR3COHet [R is a

carboxylic acid or derivative; R1 = H, OH, alkoxy or optionally substituted

cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph.,

arom. or heteroarom. group; Alk1 = optionally substituted aliphatic or

heteroarom. chain; L1 is a linker atom or group; r, s = 0, 1; Ra, Rb =

=L2(CH2)2PL3Rcq, where L2, L3 = a covalent bond or linker atom or group; p

= 0, 1; q = 1-3; Rc = H, halo, alkyl, OH, alkoxy, etc.; Alk2 = alkylene; m

= 0, 1; R2 = H, Me; R3 = H, alkyl; Het is an optionally substituted

heteroarom. group] and their salts, solvates, hydrates and N-oxides were

prepared as pharmaceutical agents. Thus, N-(2-chloronicotinoyl)-N'-(3,5-

dichloro-4-picolyl)-L-4-aminophenylalanine was prepared by coupling reaction of

N-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine Me ester with

2-chloronicotinoyl chloride followed by ester hydrolysis. Title compds.

were tested for inhibition of integrin-dependent cell adhesion and

generally have IC50 values in the 40pM and 40pM

assays of 1pM and below.

232617-97-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylalanine derivs. as pharmaceutical agents)

RN

232617-97-9 CAPLUS

1999:487274 CAPLUS

131:116520

Preparation of phenylalanine derivatives as

pharmaceutical agents

Head, John Clifford; Archibald, Sarah Catherine;

Warrellow, Graham John; Porter, John Robert

Celltech Therapeutics Limited, UK

PCT Int. Appl., 65 pp.

CODEN: PIXXD2

Patent

English

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

L6 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN L-Phenylalanine, N-[(2-acetyl-3-thienyl)carbonyl]-4-[[[3,5-dichloro-4-

pyridinyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

1999:487274 CAPLUS

131:116520

Preparation of phenylalanine derivatives as

pharmaceutical agents

Head, John Clifford; Archibald, Sarah Catherine;

Warrellow, Graham John; Porter, John Robert

Celltech Therapeutics Limited, UK

PCT Int. Appl., 65 pp.

CODEN: PIXXD2

Patent

English

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1


1

1


1

1

PAGE 1-A




PAGE 2-A




RN 226232-26-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-acetyl-N-[[[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226232-88-8 CAPLUS
 CN 3-Thiophenecarboxamide, 2-acetyl-N-[[[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 226250-84-6 CAPLUS
 CN 3-Thiophenecarboxamide, 2-acetyl-N-[[[1-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]carbonyl]-2-methylpropyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 226232-88-8
 CHF C25 H32 Cl N3 O3 S

PAGE 1-A



PAGE 2-A



CH 2

CRN 76-05-1
 CHF C2 H F3 O2



REFERENCE COUNT:



6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:115356 CAPLUS
 DOCUMENT NUMBER: 128:154011
 TITLE: Preparation of 9-thioxanthencarboxamides and 9-fluorene-carboxamides as inhibitors of microsomal triglyceride transfer protein
 INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Sulsky, Richard B.; Tino, Joseph A.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
 SOURCE: U.S., 98 pp., Cont.-in-part of U. S. Ser. No.472,067.
 CODEN: USXKAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5712279	A	19980127	US 1996-548811	19960111
CA 2091102	A1	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	T	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 9334064	A	19930909	AU 1993-34064	19930309
AU 670930	B2	19960808		
US 5739135	A	19980414	US 1995-472067	19950606
ZA 9601340	A	19970911	ZA 1996-1340	19960220
LT 4367	B	19980825	LT 1997-152	19970919
PRIORITY APPLN. INFO.:			US 1995-391901	B2 19950221
			US 1995-472067	A2 19950606
			US 1992-847503	A 19920306
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
OTHER SOURCE(S):		MARPAT 128:154011		
GI				

L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. [I; Z = a bond, S; X1, X2 = H, halo; n = 2-6; (CH2)n is optionally substituted with 1-3 substituents such as alkyl or halo; R5 = (un)substituted heteroaryl, aryl, heterocycloalkyl, cycloalkyl] and their piperidine N-oxides, which inhibit microsomal triglyceride transfer protein and thus are useful for preventing or treating atherosclerosis, pancreatitis secondary to hypertriglyceridemia, hyperglycemia, or obesity, and for lowering serum lipid levels, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, and/or hypertriglyceridemia, were prepared. Thus, reaction of 9-fluorene-carboxamide II (preparation of both reagents is described) with piperidine III in PhMe/DMF afforded the title compound I [Z = a bond; X1 = X2 = H; (CH2)n = (CH2)2CF2CH2; R5 = 2-biphenyl]. Compds. I are effective at 5-500 mg/day.

IT 182431-91-0P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 9-thioxanthencarboxamides and 9-fluorene-carboxamides as inhibitors of microsomal triglyceride transfer protein)


RI 182431-91-0 CAPLUS
 RI 3-Thiophenecarboxamide, 2-acetyl-N-[1-[4-[9-[[[2,2,2-trifluoroethyl]amino]carbonyl]-9H-fluorene-9-yl]butyl]-4-piperidinyl]-9CI (CA INDEX NAME)

L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:641305 CAPLUS
 DOCUMENT NUMBER: 125:275663
 TITLE: Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
 INVENTOR(S): Wettara, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 427 pp.
 CODEN: PINKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9626205	A1	19960829	WO 1996-US824	19960201
R: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
W: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2091102	A1	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	T	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 9334064	A	19930909	AU 1993-34064	19930309
AU 670930	B2	19960808		
US 5739135	A	19980414	US 1995-472067	19950606
AU 9647631	A	19960911	AU 1996-47631	19960201
AU 699865	B2	19981217		
EP 886637	A1	19981230	EP 1996-903604	19960201
EP 886637	B1	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11500442	T	19990112	JP 1996-525679	19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
PL 185443	B1	20030530	PL 1996-322003	19960201
AT 283851	T	20041215	AT 1996-903604	19960201
ZA 9601340	A	19970911	ZA 1996-1340	19960220
FI 9703416	A	19970820	FI 1997-3416	19970820
NO 9703821	A	19970820	NO 1997-3821	19970820
LT 4367	B	19980825	LT 1997-152	19970919
PRIORITY APPLN. INFO.:			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			US 1992-847503	A 19920306
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			WO 1996-US824	W 19960201
OTHER SOURCE(S):		MARPAT 125:275663		
GI				



AB RS23NR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzannellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SOO-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorene-carboxamide (preparation given) was alkylated by 1(CH2)4OSiMe2CHe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound 1.


IT 182431-91-0P 182435-53-6P 182437-40-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 182431-91-0 CAPLUS



CN 3-Thiophenecarboxamide, 2-acetyl-N-[1-[4-[9-[[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluorene-9-yl]butyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



● HCl


RN 182437-40-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-acetyl-N-[1-[4-[9-[[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluorene-9-yl]butyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

PAGE 1-A




PAGE 2-A



RN 182435-53-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-acetyl-N-[1-[4-[9-[[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluorene-9-yl]butyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:157721 CAPLUS

DOCUMENT NUMBER: 118:157721

TITLE: Silver halide color photographic material

INVENTOR(S): Sakai, Shuichi

PATENT ASSIGNEE(S): Fujii Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 82 pp.

CODEN: JKKKAF

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04301839	A	19921026	JP 1991-89089	19910329
PRIORITY APPLN. INFO.:			JP 1991-89089	19910329

GI



AB In the title material comprising a reflective support having thereon cyan coupler-containing silver halide emulsion layers, yellow coupler-containing silver halide emulsion layers, etc., the cyan coupler-containing silver halide layers contain one or more couplers represented by general structures I and II. For I, R1 = alkyl, alkenyl, alkynyl, etc.; X = a single bond, O, S, SO, etc.; R2 = a substituent on the benzene ring; t = 0 to 4. For II, X = C, N; Y = atoms which, together with C and X, form a 3- to 8-membered heterocyclic ring. For I and II, R3 = aryl; Z = H or a group to be released upon coupling reaction. The yellow coupler-containing silver halide emulsion layers in the title material contain an anilide coupler. The title material gives stable images.

IT 146558-33-0


RL: TEM (Technical or engineered material use); USES (Uses)

(photog. coupler)

RN 146558-33-0 CAPLUS

CN 2-Purancarboxylic acid, 3-[[[2-chloro-4-[[[(4-chlorophenyl)amino]carbonyl]amino]-5-hydroxyphenyl]amino]carbonyl]-, 2-hexyldecyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



ACCESSION NUMBER: 1992:407793 CAPLUS


DOCUMENT NUMBER: 117:7793

TITLE: Preparation of furan- and thiophenedicarboximides as herbicides
 Muenster, Peter; Freund, Wolfgang; Steiner, Gerd; Walter, Helmut; Westphalen, Karl Otto; Gerber, Matthias

PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Eur. Pat. Appl., 49 pp.
 CODEN: EPXKDW

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 467206	A2	19920122	EP 1991-111462	19910710
EP 467206	A3	19920722		
EP 467206	B1	19961218		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
DE 4023048	A1	19920123	DE 1990-4023048	19900720
AT 146475	T	19970115	AT 1991-111462	19910710
CA 2047452	A1	19920121	CA 1991-2047452	19910719
HU 58190	A2	19920228	HU 1991-2433	19910719
HU 209630	B	19940928		
JP 04234393	A	19920824	JP 1991-179867	19910719
JP 3088139	B2	20000918		
US 5276009	A	19940104	US 1991-732794	19910719
JP 2000297087	A	20001024	JP 2000-83348	19910719
JP 3169364	B2	20010521		
US 5386036	A	19950131	US 1993-110008	19930823
PRIORITY APPL. INFO.:				
			DE 1990-4023048	A 19900720
			JP 1991-179867	A3 19910719
			US 1991-732794	A3 19910719
OTHER SOURCE(S): CASREACT 117:7793; MARPAT 117:7793				
GI				




AB Title compds. [I, II; X = O, S; R1 = H, OH, (substituted) (cyclo)alkyl, heterocyclyl; R2, R3 = NO2, cyano, halo, (alkyl- or alkoxy)carbonyl-substituted] amino, (halo)alkoxy, (halo)alkylthio, (substituted) alkenyl, alkynyl, Ph, PhO, PhS, R1], were prepared as herbicides. Thus, 4-isopropylaminocarbonylthiophene-3-carboxylic acid was refluxed with SOCl2 in ClCH2CH2Cl to give 88% title compound III. I were effective against broadleaf weeds at 0.01-2 kg/ha.

IT 135278-21-6P 135278-53-4P 135278-54-5P
 135278-55-6P 135278-56-7P 135278-58-9P
 135278-59-0P 135278-60-3P 139993-22-9P


139993-23-0P 139993-24-1P 139993-25-2P
 139993-26-3P 139993-27-4P 139993-28-5P
 139993-29-6P 139993-30-9P 139993-31-0P
 139993-32-1P 139993-33-2P 139993-34-3P
 139993-35-4P 139993-36-5P 139993-37-6P
 140128-97-8P

RL: SPH (Synthetic preparation); PREP (Preparation)
 (preph. of, as intermediate for dicarboximide herbicide)


RN 135278-21-6 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-chloro-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-53-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[1-methylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-54-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-55-6 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-56-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[1,1-dimethylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-58-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-chloro-3-[[[1,1-dimethylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-59-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-chloro-3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-60-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-chloro-3-[[[1-methylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-22-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-cyano-3-[[[1-methylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 139993-23-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-chloro-3-[[[1,1-dimethylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-24-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 4,5-dichloro-3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-25-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-bromo-3-[(cyclopropylamino)carbonyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2-Thiophenecarboxylic acid, 4,5-dichloro-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)





RN 139993-30-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(cyclopropylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-31-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-chloro-3-[(cyclopropylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-32-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-bromo-3-[[[1,1-dimethylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-26-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-bromo-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 139993-27-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 4,5-dichloro-3-[[[1,1-dimethylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-28-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 4,5-dichloro-3-[(cyclopropylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-29-6 CAPLUS


RN 139993-33-2 CAPLUS
CN 2-Furancarboxylic acid, 3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-34-3 CAPLUS
CN 2-Furancarboxylic acid, 3-[[[4-chlorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-35-4 CAPLUS
CN 2-Furancarboxylic acid, 3-[[[2-fluorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-36-5 CAPLUS
CN 2-Furancarboxylic acid, 3-[(cyclohexylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 139993-37-6 CAPLUS
CN 2-Furancarboxylic acid, 3-[[[(1,1-dimethylethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 140128-97-8 CAPLUS
CN 2-Furancarboxylic acid, 3-[[[(1-cyano-1-methylethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




study); PREP (Preparation)
(prepn. and herbicidal activity of)
RN 135278-21-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-chloro-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 135278-53-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(1-methylethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-54-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 135278-55-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)

1991:471383 CAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER: 115:71383
TITLE: Preparation of thiophene- and tetrahydrofuran carboxylic acid amides as herbicides
INVENTOR(S): Muenster, Peter; Steiner, Gerd; Freund, Wolfgang; Wuerzler, Bruno; Westphalen, Karl Otto
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 53 pp.
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3933573	A1	19910418	DE 1989-3933573	19891007
EP 423523	A2	19910424	EP 1990-118654	19900928
EP 423523	A3	19920219		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
CA 2026829	A1	19910408	CA 1990-2026829	19901003
US 5201934	A	19930413	US 1990-592287	19901003
HU 55377	A2	19910528	HU 1990-6362	19901005
JP 03127787	A	19910530	JP 1990-266572	19901005
US 5258357	A	19931102	US 1992-947538	19920921
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):		MARPAT 115:71383		
GI				




AB Preparation of title compds. I-III (X = O, S, R1 = H, alkyl, cycloalkyl, R2 =

OH, alkoxyl, cyanoalkyl, substituted alkenyl, alkynyl, Ph, naphthyl etc.; R1R2 = 4-7 ring compounds; R3, R4 = NO2, CN, halo, substituted amino, alkoxyl, alkylthio, heterocyclic etc.; R5 = formyl, 4,5-dihydrooxazol-2-yl, alkoxycarbonyl, thiocarbonyl, carboxy etc.) as herbicides are claimed. Thus, reaction of thiophene-3,4-dicarboxylic acid with Ac2O gave 98% thiophene-3,4-dicarboxylic acid anhydride which on amidation with 4-ClC6H4NH2 in PhMe gave 100% I (R1 = R3 = R4 = H, R2 = 4-ClC6H4, R5 = CO2H, X = S).


IT 135278-21-6P 135278-53-4P 135278-54-5P
135278-55-6P 135278-56-7P 135278-57-8P
135278-58-9P 135278-59-0P 135278-60-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological




RN 135278-56-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(1,1-dimethylethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 135278-57-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 135278-58-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-chloro-3-[[[(1,1-dimethylethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 135278-59-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-chloro-3-[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 135278-60-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-chloro-3-[[[(1-methylethyl)amino]carbonyl]-
(9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1927:23577 CAPLUS
DOCUMENT NUMBER: 21:23577
ORIGINAL REFERENCE NO.: 21:2896e-1,2897a-b
TITLE: Elsholtzia ketone, a contribution to furan chemistry
AUTHOR(S): Asahina, Yasuhiko; Murayama, Y.; Shibata, B.;
Kariyone, T.; Kuwada, S.; Asano, M.
SOURCE: Acta Phytoclimica (1924), 2, 1-23
CODEN: APCJAS; ISSN: 0365-5393
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The oil of Elsholtzia cristata contains a furan ketone, C10H14O2, elsholtzia ketone, which with KMnO4 yielded isovaleric acid. This indicated that the ketone is a methylfuran iso-Bu compound, but the location of the Me and ketonic groups on the furan nucleus had not been established. EtONa and Na produced isobutyraldoximes and C6H5O3, elsholtzia acid (II), together with some ester. I gave a K salt, C6H5O3Na, C6H5O3Na.H2O, (C6H5O3)2Ca, (C6H5O3)2Ba, (C6H5O3)2Pb.H2O, C6H5O3Ag, (C6H5O3)2Cu, (C6H5O3)2Cu.H2O (C6H5O3)2FeOH and (C6H5O3)2Fe2O.9H2O, Me ester, m. 35-8°, while the Et ester, C8H10O3, m. 47-8°, b. 205°/SOCl2 produced a chloride, C6H5O2Cl, (II), m. 21-2°, b. 192°. NH3 with II gave an amide, m. 85-6°, and PhNH2 gave an anilide, m. 91°. With H2SO4 II gave an amide, m. 85-6°, and PhNH2 gave an anilide, m. 91°. With H2SO5 yielded a sirup, presumably impure citraconic acid, which, on catalytic reduction, produced pyrotartaric acid. I is a methylfurancarboxylic acid. Various unsuccessful attempts were made to determine the orientation of this acid by preparing a furylacrylic acid. In this connection the Et ester of I was condensed with AcOEt producing C4H2O(Me)COCH2CO2Et, Et elsholtziacylacetate, yellowish and viscous, b15 145-50°, d417 1.1437, nD19 1.50044. An alc. solution gave a violet-red color with FeCl3. NH2OH did not yield an oxime, but when heated produced an isoxazolone derivative, C8H7NO3, m. 95°. By treating II, hot, in direct sunlight with Br2 an oil was obtained, which, with hot H2O, yielded C6H4O4, furan-3-aldehyde-2-carboxylic acid (III) m. 158°. The aqueous solution reduced NH3-AgNO3 and reddened Schiff's reagent. It gave a yellow phenylhydrazone, C12H10O3N2, sintering 166°, and m. 171° (decomposition). The oxime, C6H4O4N, m. 225°, and heated with Ac2O yielded 3-cyano-2-furancarboxylic acid, C6H3O3N, m. 183°. With NH3-AgNO3 III produced C6H4O5, furan-2,3-dicarboxylic acid, m. 221°. This acid did not give an anhydride with AcCl or Ac2O; it sublimed unchanged in vacuo. Fused with resorcinol and ZnCl2 it gave a substance fluorescing yellowish green with alkalis. The di-Me ester, m. 37°, and the monoanilide, m. 170°. The identity of this acid was proved by its synthesis by similar reactions from 2-methylfuran-3-carboxylic acid. As an intermediate product in this synthesis, there resulted yellow C6H6O4Br, 2-hydroxymethylbromofuran-3-carboxylic acid, m. 116°, and without reducing power the acetate, C8H7O5Br, m. 94-5°. Heating I in a closed tube at 210-30° produced 3-methylfuran, C5H6O, b. 65.5°, d418 0.923, nD18 1.4255, mol. refraction 22.74. This colored a pine splint moistened with HCl blue-green, and a saturated vanillin solution in concentrated HCl first red, then violet. This color-reagent proved more valuable than the pine splint and the effects of 21 furan derivs. upon it are recorded. I is 3-methylfuran-2-carboxylic acid, and elsholtzia ketone is 3-methyl-2-isovaleryl-furan.

IT 139993-33-2P, Pyromucic acid, 3-phenylcarbamyl-
RL: PREP (Preparation)
(preparation of)

RN 139993-33-2 CAPLUS

